nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Dacarbazine—muscle cancer	0.0754	0.174	CbGbCtD
Ziprasidone—CYP3A7—Vincristine—muscle cancer	0.0721	0.166	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0721	0.166	CbGbCtD
Ziprasidone—CYP3A5—Vincristine—muscle cancer	0.0541	0.124	CbGbCtD
Ziprasidone—CYP3A5—Etoposide—muscle cancer	0.0496	0.114	CbGbCtD
Ziprasidone—CYP1A2—Etoposide—muscle cancer	0.0369	0.0849	CbGbCtD
Ziprasidone—CYP3A4—Vincristine—muscle cancer	0.0211	0.0485	CbGbCtD
Ziprasidone—CYP2D6—Doxorubicin—muscle cancer	0.0207	0.0477	CbGbCtD
Ziprasidone—CYP3A4—Etoposide—muscle cancer	0.0193	0.0445	CbGbCtD
Ziprasidone—CHRM3—muscle of abdomen—muscle cancer	0.0144	0.112	CbGeAlD
Ziprasidone—CYP3A4—Doxorubicin—muscle cancer	0.0132	0.0303	CbGbCtD
Ziprasidone—HTR2A—hindlimb—muscle cancer	0.00438	0.0342	CbGeAlD
Ziprasidone—HTR2A—appendage—muscle cancer	0.00376	0.0293	CbGeAlD
Ziprasidone—H1F0—embryo—muscle cancer	0.00324	0.0253	CbGeAlD
Ziprasidone—DRD4—testis—muscle cancer	0.00311	0.0243	CbGeAlD
Ziprasidone—HTR1E—head—muscle cancer	0.00278	0.0217	CbGeAlD
Ziprasidone—ADRA1B—renal system—muscle cancer	0.0026	0.0203	CbGeAlD
Ziprasidone—H1F0—smooth muscle tissue—muscle cancer	0.00255	0.0199	CbGeAlD
Ziprasidone—H1F0—renal system—muscle cancer	0.00246	0.0192	CbGeAlD
Ziprasidone—CHRM4—head—muscle cancer	0.00244	0.019	CbGeAlD
Ziprasidone—CHRM4—testis—muscle cancer	0.00235	0.0184	CbGeAlD
Ziprasidone—DRD3—head—muscle cancer	0.00227	0.0177	CbGeAlD
Ziprasidone—H1F0—cardiac atrium—muscle cancer	0.0022	0.0172	CbGeAlD
Ziprasidone—HTR6—head—muscle cancer	0.00218	0.017	CbGeAlD
Ziprasidone—DRD5—head—muscle cancer	0.00212	0.0166	CbGeAlD
Ziprasidone—H1F0—tendon—muscle cancer	0.00192	0.015	CbGeAlD
Ziprasidone—CHRM5—head—muscle cancer	0.00191	0.0149	CbGeAlD
Ziprasidone—H1F0—bone marrow—muscle cancer	0.00186	0.0145	CbGeAlD
Ziprasidone—H1F0—vagina—muscle cancer	0.00178	0.0139	CbGeAlD
Ziprasidone—ADRA1B—head—muscle cancer	0.00174	0.0136	CbGeAlD
Ziprasidone—CHRM3—smooth muscle tissue—muscle cancer	0.00165	0.0129	CbGeAlD
Ziprasidone—H1F0—head—muscle cancer	0.00164	0.0128	CbGeAlD
Ziprasidone—DRD1—head—muscle cancer	0.00162	0.0127	CbGeAlD
Ziprasidone—CHRM3—renal system—muscle cancer	0.00159	0.0124	CbGeAlD
Ziprasidone—H1F0—testis—muscle cancer	0.00159	0.0124	CbGeAlD
Ziprasidone—HTR1A—renal system—muscle cancer	0.00159	0.0124	CbGeAlD
Ziprasidone—HTR7—smooth muscle tissue—muscle cancer	0.00157	0.0123	CbGeAlD
Ziprasidone—HTR3A—head—muscle cancer	0.00157	0.0122	CbGeAlD
Ziprasidone—HTR7—renal system—muscle cancer	0.00152	0.0118	CbGeAlD
Ziprasidone—ADRA1A—renal system—muscle cancer	0.00146	0.0114	CbGeAlD
Ziprasidone—KCNH2—renal system—muscle cancer	0.00141	0.011	CbGeAlD
Ziprasidone—ADRA2C—renal system—muscle cancer	0.00139	0.0109	CbGeAlD
Ziprasidone—HTR1B—head—muscle cancer	0.00131	0.0103	CbGeAlD
Ziprasidone—CHRM2—head—muscle cancer	0.00131	0.0102	CbGeAlD
Ziprasidone—HTR1D—head—muscle cancer	0.00127	0.00993	CbGeAlD
Ziprasidone—KCNH2—cardiac atrium—muscle cancer	0.00126	0.00986	CbGeAlD
Ziprasidone—HTR2C—head—muscle cancer	0.00126	0.00983	CbGeAlD
Ziprasidone—HTR2A—embryo—muscle cancer	0.00125	0.00974	CbGeAlD
Ziprasidone—ADRA2C—cardiac atrium—muscle cancer	0.00125	0.00973	CbGeAlD
Ziprasidone—CYP1A2—renal system—muscle cancer	0.00121	0.00943	CbGeAlD
Ziprasidone—SLC6A4—head—muscle cancer	0.0012	0.00932	CbGeAlD
Ziprasidone—CHRM1—head—muscle cancer	0.00119	0.00928	CbGeAlD
Ziprasidone—HTR7—tendon—muscle cancer	0.00118	0.00923	CbGeAlD
Ziprasidone—HRH1—smooth muscle tissue—muscle cancer	0.00118	0.00917	CbGeAlD
Ziprasidone—CYP3A5—renal system—muscle cancer	0.00117	0.00909	CbGeAlD
Ziprasidone—ADRA2C—tendon—muscle cancer	0.00109	0.00848	CbGeAlD
Ziprasidone—KCNH2—bone marrow—muscle cancer	0.00107	0.00833	CbGeAlD
Ziprasidone—CHRM3—head—muscle cancer	0.00107	0.00831	CbGeAlD
Ziprasidone—HTR1A—head—muscle cancer	0.00106	0.00828	CbGeAlD
Ziprasidone—CHRM3—testis—muscle cancer	0.00103	0.00803	CbGeAlD
Ziprasidone—KCNH2—vagina—muscle cancer	0.00102	0.00798	CbGeAlD
Ziprasidone—HTR7—head—muscle cancer	0.00101	0.00791	CbGeAlD
Ziprasidone—ADRA2C—vagina—muscle cancer	0.00101	0.00787	CbGeAlD
Ziprasidone—ADRA2A—cardiac atrium—muscle cancer	0.000995	0.00776	CbGeAlD
Ziprasidone—HTR2A—smooth muscle tissue—muscle cancer	0.000982	0.00766	CbGeAlD
Ziprasidone—HTR7—testis—muscle cancer	0.00098	0.00764	CbGeAlD
Ziprasidone—ADRA1A—head—muscle cancer	0.000978	0.00763	CbGeAlD
Ziprasidone—DRD2—head—muscle cancer	0.000959	0.00748	CbGeAlD
Ziprasidone—HTR2A—renal system—muscle cancer	0.000945	0.00737	CbGeAlD
Ziprasidone—KCNH2—head—muscle cancer	0.000945	0.00737	CbGeAlD
Ziprasidone—ADRA2C—head—muscle cancer	0.000932	0.00727	CbGeAlD
Ziprasidone—DRD2—testis—muscle cancer	0.000926	0.00722	CbGeAlD
Ziprasidone—KCNH2—testis—muscle cancer	0.000913	0.00712	CbGeAlD
Ziprasidone—ADRA2C—testis—muscle cancer	0.0009	0.00702	CbGeAlD
Ziprasidone—HRH1—tendon—muscle cancer	0.000883	0.00689	CbGeAlD
Ziprasidone—CYP3A4—renal system—muscle cancer	0.000875	0.00682	CbGeAlD
Ziprasidone—ADRA2A—tendon—muscle cancer	0.000868	0.00677	CbGeAlD
Ziprasidone—CYP2D6—renal system—muscle cancer	0.000861	0.00672	CbGeAlD
Ziprasidone—CYP3A5—vagina—muscle cancer	0.000844	0.00659	CbGeAlD
Ziprasidone—HRH1—vagina—muscle cancer	0.00082	0.00639	CbGeAlD
Ziprasidone—ADRA2A—vagina—muscle cancer	0.000805	0.00628	CbGeAlD
Ziprasidone—HRH1—head—muscle cancer	0.000757	0.00591	CbGeAlD
Ziprasidone—ADRA2A—head—muscle cancer	0.000744	0.0058	CbGeAlD
Ziprasidone—HTR2A—tendon—muscle cancer	0.000738	0.00575	CbGeAlD
Ziprasidone—HRH1—testis—muscle cancer	0.000731	0.0057	CbGeAlD
Ziprasidone—ADRA2A—testis—muscle cancer	0.000718	0.0056	CbGeAlD
Ziprasidone—HTR2A—vagina—muscle cancer	0.000685	0.00534	CbGeAlD
Ziprasidone—Paraesthesia—Vincristine—muscle cancer	0.000659	0.00151	CcSEcCtD
Ziprasidone—Dermatitis bullous—Doxorubicin—muscle cancer	0.000656	0.00151	CcSEcCtD
Ziprasidone—Breast disorder—Methotrexate—muscle cancer	0.000654	0.0015	CcSEcCtD
Ziprasidone—Vertigo—Etoposide—muscle cancer	0.000654	0.0015	CcSEcCtD
Ziprasidone—Leukopenia—Etoposide—muscle cancer	0.000652	0.0015	CcSEcCtD
Ziprasidone—Abdominal pain—Dactinomycin—muscle cancer	0.000649	0.00149	CcSEcCtD
Ziprasidone—Body temperature increased—Dactinomycin—muscle cancer	0.000649	0.00149	CcSEcCtD
Ziprasidone—Hypoglycaemia—Doxorubicin—muscle cancer	0.000642	0.00148	CcSEcCtD
Ziprasidone—Loss of consciousness—Etoposide—muscle cancer	0.00064	0.00147	CcSEcCtD
Ziprasidone—Lethargy—Doxorubicin—muscle cancer	0.00064	0.00147	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00064	0.00147	CcSEcCtD
Ziprasidone—Decreased appetite—Vincristine—muscle cancer	0.000638	0.00147	CcSEcCtD
Ziprasidone—Cough—Etoposide—muscle cancer	0.000635	0.00146	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Vincristine—muscle cancer	0.000633	0.00146	CcSEcCtD
Ziprasidone—HTR2A—head—muscle cancer	0.000632	0.00493	CbGeAlD
Ziprasidone—Fatigue—Vincristine—muscle cancer	0.000632	0.00145	CcSEcCtD
Ziprasidone—Hyponatraemia—Doxorubicin—muscle cancer	0.000629	0.00145	CcSEcCtD
Ziprasidone—Hypertension—Etoposide—muscle cancer	0.000628	0.00145	CcSEcCtD
Ziprasidone—Constipation—Vincristine—muscle cancer	0.000627	0.00144	CcSEcCtD
Ziprasidone—Osteoarthritis—Doxorubicin—muscle cancer	0.000627	0.00144	CcSEcCtD
Ziprasidone—Diplopia—Doxorubicin—muscle cancer	0.000627	0.00144	CcSEcCtD
Ziprasidone—Pain in extremity—Doxorubicin—muscle cancer	0.000627	0.00144	CcSEcCtD
Ziprasidone—Chest pain—Etoposide—muscle cancer	0.00062	0.00142	CcSEcCtD
Ziprasidone—Eosinophilia—Methotrexate—muscle cancer	0.00062	0.00142	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000615	0.00142	CcSEcCtD
Ziprasidone—HTR2A—testis—muscle cancer	0.000611	0.00476	CbGeAlD
Ziprasidone—Face oedema—Doxorubicin—muscle cancer	0.000605	0.00139	CcSEcCtD
Ziprasidone—Hypersensitivity—Dactinomycin—muscle cancer	0.000605	0.00139	CcSEcCtD
Ziprasidone—Abdominal discomfort—Methotrexate—muscle cancer	0.0006	0.00138	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Vincristine—muscle cancer	0.0006	0.00138	CcSEcCtD
Ziprasidone—Confusional state—Etoposide—muscle cancer	0.000599	0.00138	CcSEcCtD
Ziprasidone—Infection—Etoposide—muscle cancer	0.00059	0.00136	CcSEcCtD
Ziprasidone—Ataxia—Doxorubicin—muscle cancer	0.000589	0.00136	CcSEcCtD
Ziprasidone—Asthenia—Dactinomycin—muscle cancer	0.000589	0.00135	CcSEcCtD
Ziprasidone—Blood creatinine increased—Doxorubicin—muscle cancer	0.000587	0.00135	CcSEcCtD
Ziprasidone—Dysuria—Methotrexate—muscle cancer	0.000585	0.00135	CcSEcCtD
Ziprasidone—Dehydration—Doxorubicin—muscle cancer	0.000583	0.00134	CcSEcCtD
Ziprasidone—Thrombocytopenia—Etoposide—muscle cancer	0.000582	0.00134	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000582	0.00134	CcSEcCtD
Ziprasidone—Tachycardia—Etoposide—muscle cancer	0.00058	0.00133	CcSEcCtD
Ziprasidone—Body temperature increased—Vincristine—muscle cancer	0.00058	0.00133	CcSEcCtD
Ziprasidone—Abdominal pain—Vincristine—muscle cancer	0.00058	0.00133	CcSEcCtD
Ziprasidone—Liver function test abnormal—Doxorubicin—muscle cancer	0.000579	0.00133	CcSEcCtD
Ziprasidone—Skin disorder—Etoposide—muscle cancer	0.000577	0.00133	CcSEcCtD
Ziprasidone—Erectile dysfunction—Methotrexate—muscle cancer	0.000576	0.00133	CcSEcCtD
Ziprasidone—CYP2D6—head—muscle cancer	0.000576	0.00449	CbGeAlD
Ziprasidone—Hyperhidrosis—Etoposide—muscle cancer	0.000574	0.00132	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000573	0.00132	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Methotrexate—muscle cancer	0.000571	0.00131	CcSEcCtD
Ziprasidone—Hypokalaemia—Doxorubicin—muscle cancer	0.000571	0.00131	CcSEcCtD
Ziprasidone—Breast disorder—Doxorubicin—muscle cancer	0.000567	0.0013	CcSEcCtD
Ziprasidone—Anorexia—Etoposide—muscle cancer	0.000566	0.0013	CcSEcCtD
Ziprasidone—Diarrhoea—Dactinomycin—muscle cancer	0.000562	0.00129	CcSEcCtD
Ziprasidone—Pneumonia—Methotrexate—muscle cancer	0.000561	0.00129	CcSEcCtD
Ziprasidone—Nasopharyngitis—Doxorubicin—muscle cancer	0.000561	0.00129	CcSEcCtD
Ziprasidone—Infestation NOS—Methotrexate—muscle cancer	0.000558	0.00128	CcSEcCtD
Ziprasidone—Infestation—Methotrexate—muscle cancer	0.000558	0.00128	CcSEcCtD
Ziprasidone—CYP2D6—testis—muscle cancer	0.000556	0.00434	CbGeAlD
Ziprasidone—Hypotension—Etoposide—muscle cancer	0.000555	0.00128	CcSEcCtD
Ziprasidone—Gastritis—Doxorubicin—muscle cancer	0.000555	0.00128	CcSEcCtD
Ziprasidone—Renal failure—Methotrexate—muscle cancer	0.000548	0.00126	CcSEcCtD
Ziprasidone—Conjunctivitis—Methotrexate—muscle cancer	0.000542	0.00125	CcSEcCtD
Ziprasidone—Influenza—Doxorubicin—muscle cancer	0.000542	0.00125	CcSEcCtD
Ziprasidone—Dysphagia—Doxorubicin—muscle cancer	0.000542	0.00125	CcSEcCtD
Ziprasidone—Hypersensitivity—Vincristine—muscle cancer	0.00054	0.00124	CcSEcCtD
Ziprasidone—Eosinophilia—Doxorubicin—muscle cancer	0.000536	0.00123	CcSEcCtD
Ziprasidone—Sweating—Methotrexate—muscle cancer	0.000535	0.00123	CcSEcCtD
Ziprasidone—Paraesthesia—Etoposide—muscle cancer	0.000533	0.00123	CcSEcCtD
Ziprasidone—Haematuria—Methotrexate—muscle cancer	0.000532	0.00122	CcSEcCtD
Ziprasidone—Dyspnoea—Etoposide—muscle cancer	0.00053	0.00122	CcSEcCtD
Ziprasidone—Somnolence—Etoposide—muscle cancer	0.000528	0.00121	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—muscle cancer	0.000528	0.00121	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—muscle cancer	0.000526	0.00121	CcSEcCtD
Ziprasidone—Asthenia—Vincristine—muscle cancer	0.000526	0.00121	CcSEcCtD
Ziprasidone—Vomiting—Dactinomycin—muscle cancer	0.000522	0.0012	CcSEcCtD
Ziprasidone—Rash—Dactinomycin—muscle cancer	0.000518	0.00119	CcSEcCtD
Ziprasidone—Decreased appetite—Etoposide—muscle cancer	0.000516	0.00119	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Etoposide—muscle cancer	0.000513	0.00118	CcSEcCtD
Ziprasidone—Fatigue—Etoposide—muscle cancer	0.000512	0.00118	CcSEcCtD
Ziprasidone—Constipation—Etoposide—muscle cancer	0.000508	0.00117	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—muscle cancer	0.000507	0.00117	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000504	0.00116	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—muscle cancer	0.000503	0.00116	CcSEcCtD
Ziprasidone—Diarrhoea—Vincristine—muscle cancer	0.000502	0.00115	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—muscle cancer	0.000501	0.00115	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—muscle cancer	0.000501	0.00115	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—muscle cancer	0.000497	0.00114	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—muscle cancer	0.000495	0.00114	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000495	0.00114	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—muscle cancer	0.000493	0.00113	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—muscle cancer	0.000491	0.00113	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—muscle cancer	0.00049	0.00113	CcSEcCtD
Ziprasidone—Feeling abnormal—Etoposide—muscle cancer	0.00049	0.00113	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—muscle cancer	0.000489	0.00112	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—muscle cancer	0.000488	0.00112	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—muscle cancer	0.000486	0.00112	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Etoposide—muscle cancer	0.000486	0.00112	CcSEcCtD
Ziprasidone—Dizziness—Vincristine—muscle cancer	0.000485	0.00112	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—muscle cancer	0.000483	0.00111	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—muscle cancer	0.000483	0.00111	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—muscle cancer	0.000483	0.00111	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—muscle cancer	0.000475	0.00109	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000474	0.00109	CcSEcCtD
Ziprasidone—Urticaria—Etoposide—muscle cancer	0.000472	0.00109	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—muscle cancer	0.000471	0.00108	CcSEcCtD
Ziprasidone—Abdominal pain—Etoposide—muscle cancer	0.00047	0.00108	CcSEcCtD
Ziprasidone—Body temperature increased—Etoposide—muscle cancer	0.00047	0.00108	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—muscle cancer	0.00047	0.00108	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—muscle cancer	0.000468	0.00108	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—muscle cancer	0.000467	0.00107	CcSEcCtD
Ziprasidone—Vomiting—Vincristine—muscle cancer	0.000466	0.00107	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—muscle cancer	0.000465	0.00107	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—muscle cancer	0.000463	0.00106	CcSEcCtD
Ziprasidone—Rash—Vincristine—muscle cancer	0.000462	0.00106	CcSEcCtD
Ziprasidone—Dermatitis—Vincristine—muscle cancer	0.000462	0.00106	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—muscle cancer	0.000461	0.00106	CcSEcCtD
Ziprasidone—Headache—Vincristine—muscle cancer	0.000459	0.00106	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—muscle cancer	0.000456	0.00105	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—muscle cancer	0.000454	0.00104	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—muscle cancer	0.000452	0.00104	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—muscle cancer	0.000451	0.00104	CcSEcCtD
Ziprasidone—Chills—Methotrexate—muscle cancer	0.000449	0.00103	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—muscle cancer	0.000443	0.00102	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—muscle cancer	0.000442	0.00102	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—muscle cancer	0.000439	0.00101	CcSEcCtD
Ziprasidone—Hypersensitivity—Etoposide—muscle cancer	0.000438	0.00101	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—muscle cancer	0.000436	0.001	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—muscle cancer	0.000436	0.001	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—muscle cancer	0.000436	0.001	CcSEcCtD
Ziprasidone—Nausea—Vincristine—muscle cancer	0.000436	0.001	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—muscle cancer	0.000435	0.001	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—muscle cancer	0.000434	0.000997	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—muscle cancer	0.000434	0.000997	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—muscle cancer	0.000432	0.000992	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—muscle cancer	0.00043	0.00099	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—muscle cancer	0.000428	0.000985	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—muscle cancer	0.000427	0.000982	CcSEcCtD
Ziprasidone—Asthenia—Etoposide—muscle cancer	0.000426	0.00098	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—muscle cancer	0.000426	0.00098	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—muscle cancer	0.000425	0.000978	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—muscle cancer	0.000422	0.00097	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—muscle cancer	0.000418	0.000961	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—muscle cancer	0.000411	0.000945	CcSEcCtD
Ziprasidone—Diarrhoea—Etoposide—muscle cancer	0.000406	0.000935	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—muscle cancer	0.000405	0.000932	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—muscle cancer	0.000404	0.00093	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—muscle cancer	0.000403	0.000927	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—muscle cancer	0.000403	0.000926	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—muscle cancer	0.000393	0.000905	CcSEcCtD
Ziprasidone—Dizziness—Etoposide—muscle cancer	0.000393	0.000903	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—muscle cancer	0.000392	0.000901	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—muscle cancer	0.000392	0.000901	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—muscle cancer	0.000391	0.000899	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—muscle cancer	0.00039	0.000897	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—muscle cancer	0.000389	0.000895	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—muscle cancer	0.000387	0.000891	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—muscle cancer	0.000383	0.000881	CcSEcCtD
Ziprasidone—Cough—Methotrexate—muscle cancer	0.00038	0.000875	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—muscle cancer	0.00038	0.000874	CcSEcCtD
Ziprasidone—Vomiting—Etoposide—muscle cancer	0.000378	0.000869	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—muscle cancer	0.000378	0.000868	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—muscle cancer	0.000378	0.000868	CcSEcCtD
Ziprasidone—Rash—Etoposide—muscle cancer	0.000375	0.000861	CcSEcCtD
Ziprasidone—Dermatitis—Etoposide—muscle cancer	0.000374	0.00086	CcSEcCtD
Ziprasidone—Headache—Etoposide—muscle cancer	0.000372	0.000856	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—muscle cancer	0.000372	0.000855	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—muscle cancer	0.000371	0.000854	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—muscle cancer	0.000371	0.000854	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—muscle cancer	0.000371	0.000854	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000369	0.000848	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—muscle cancer	0.000365	0.00084	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—muscle cancer	0.000363	0.000835	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—muscle cancer	0.000359	0.000825	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—muscle cancer	0.000356	0.000818	CcSEcCtD
Ziprasidone—Infection—Methotrexate—muscle cancer	0.000354	0.000813	CcSEcCtD
Ziprasidone—Nausea—Etoposide—muscle cancer	0.000353	0.000811	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—muscle cancer	0.000349	0.000802	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—muscle cancer	0.000349	0.000802	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—muscle cancer	0.000348	0.000801	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—muscle cancer	0.000347	0.000798	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—muscle cancer	0.000346	0.000795	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—muscle cancer	0.000344	0.000791	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—muscle cancer	0.000339	0.00078	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—muscle cancer	0.000339	0.00078	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—muscle cancer	0.000339	0.000779	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—muscle cancer	0.000338	0.000777	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—muscle cancer	0.000334	0.000767	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—muscle cancer	0.000333	0.000765	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—muscle cancer	0.000332	0.000763	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—muscle cancer	0.000329	0.000758	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—muscle cancer	0.000326	0.00075	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000324	0.000745	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—muscle cancer	0.000322	0.00074	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—muscle cancer	0.000321	0.000739	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—muscle cancer	0.000321	0.000739	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—muscle cancer	0.000321	0.000739	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—muscle cancer	0.00032	0.000737	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—muscle cancer	0.00032	0.000735	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000319	0.000734	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—muscle cancer	0.000317	0.000729	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—muscle cancer	0.000316	0.000727	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—muscle cancer	0.000314	0.000723	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—muscle cancer	0.000313	0.00072	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—muscle cancer	0.000311	0.000714	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—muscle cancer	0.000309	0.000711	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000307	0.000706	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—muscle cancer	0.000307	0.000705	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—muscle cancer	0.000306	0.000704	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—muscle cancer	0.000303	0.000697	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—muscle cancer	0.000302	0.000695	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—muscle cancer	0.000302	0.000694	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—muscle cancer	0.000301	0.000691	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—muscle cancer	0.000299	0.000688	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—muscle cancer	0.000298	0.000685	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—muscle cancer	0.000294	0.000675	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—muscle cancer	0.000293	0.000674	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—muscle cancer	0.000291	0.000669	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—muscle cancer	0.000288	0.000662	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—muscle cancer	0.000283	0.00065	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—muscle cancer	0.000281	0.000647	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—muscle cancer	0.000281	0.000647	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000281	0.000646	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—muscle cancer	0.000279	0.000641	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—muscle cancer	0.000277	0.000636	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—muscle cancer	0.000275	0.000632	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—muscle cancer	0.000274	0.00063	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—muscle cancer	0.000271	0.000624	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—muscle cancer	0.000268	0.000616	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000266	0.000612	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—muscle cancer	0.000266	0.000611	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—muscle cancer	0.000263	0.000606	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—muscle cancer	0.000262	0.000603	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—muscle cancer	0.000255	0.000587	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—muscle cancer	0.000254	0.000584	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000252	0.000579	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—muscle cancer	0.000245	0.000563	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—muscle cancer	0.000244	0.00056	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—muscle cancer	0.000244	0.00056	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—muscle cancer	0.000243	0.00056	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—muscle cancer	0.000235	0.000541	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—muscle cancer	0.000227	0.000522	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—muscle cancer	0.000226	0.00052	CcSEcCtD
Ziprasidone—Rash—Methotrexate—muscle cancer	0.000224	0.000516	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—muscle cancer	0.000224	0.000515	CcSEcCtD
Ziprasidone—Headache—Methotrexate—muscle cancer	0.000223	0.000513	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—muscle cancer	0.000221	0.000508	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—muscle cancer	0.000211	0.000486	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—muscle cancer	0.000211	0.000485	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—muscle cancer	0.000204	0.000469	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—muscle cancer	0.000196	0.00045	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—muscle cancer	0.000194	0.000447	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—muscle cancer	0.000194	0.000446	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—muscle cancer	0.000193	0.000444	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—muscle cancer	0.000183	0.000421	CcSEcCtD
Ziprasidone—HTR1B—Signaling Pathways—PTCH1—muscle cancer	2.11e-06	0.000912	CbGpPWpGaD
Ziprasidone—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.09e-06	0.000904	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PTCH1—muscle cancer	2.08e-06	0.000897	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PTCH1—muscle cancer	2.05e-06	0.000885	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—ENO2—muscle cancer	2.02e-06	0.000873	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—FOXO1—muscle cancer	2.02e-06	0.000873	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—CNR1—muscle cancer	2.02e-06	0.000872	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—FH—muscle cancer	2.02e-06	0.000871	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—CNR1—muscle cancer	1.99e-06	0.000859	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—CNR1—muscle cancer	1.99e-06	0.000858	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—CNR1—muscle cancer	1.98e-06	0.000856	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—CNR1—muscle cancer	1.98e-06	0.000853	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—CNR1—muscle cancer	1.97e-06	0.00085	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—ENO2—muscle cancer	1.96e-06	0.000848	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PTCH1—muscle cancer	1.96e-06	0.000848	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—CNR1—muscle cancer	1.95e-06	0.000842	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—CNR1—muscle cancer	1.95e-06	0.00084	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IGF2—muscle cancer	1.94e-06	0.000839	CbGpPWpGaD
Ziprasidone—DRD2—Circadian rythm related genes—TP53—muscle cancer	1.91e-06	0.000823	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—MED12—muscle cancer	1.91e-06	0.000823	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PTCH1—muscle cancer	1.87e-06	0.000808	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—FOXO4—muscle cancer	1.87e-06	0.000807	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—FOXO4—muscle cancer	1.87e-06	0.000806	CbGpPWpGaD
Ziprasidone—CHRM1—Circadian rythm related genes—TP53—muscle cancer	1.87e-06	0.000806	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—FOXO4—muscle cancer	1.86e-06	0.000801	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PTCH1—muscle cancer	1.85e-06	0.000797	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CNR1—muscle cancer	1.84e-06	0.000792	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CNR1—muscle cancer	1.83e-06	0.000791	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CNR1—muscle cancer	1.82e-06	0.000786	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—FOXO4—muscle cancer	1.82e-06	0.000784	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CNR1—muscle cancer	1.81e-06	0.00078	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—FOXO1—muscle cancer	1.79e-06	0.000772	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—FOXO4—muscle cancer	1.79e-06	0.000772	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CNR1—muscle cancer	1.78e-06	0.00077	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—FOXO4—muscle cancer	1.76e-06	0.000761	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CNR1—muscle cancer	1.75e-06	0.000757	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—MED12—muscle cancer	1.75e-06	0.000756	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—ENO2—muscle cancer	1.74e-06	0.000751	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CNR1—muscle cancer	1.73e-06	0.000747	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—FH—muscle cancer	1.71e-06	0.000738	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—FOXO4—muscle cancer	1.69e-06	0.000729	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PTCH1—muscle cancer	1.67e-06	0.00072	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CNR1—muscle cancer	1.66e-06	0.000716	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTCH1—muscle cancer	1.61e-06	0.000695	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—FOXO4—muscle cancer	1.61e-06	0.000695	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—MED12—muscle cancer	1.6e-06	0.000692	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTCH1—muscle cancer	1.6e-06	0.000691	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—ENO2—muscle cancer	1.6e-06	0.000689	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—FOXO4—muscle cancer	1.59e-06	0.000685	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CNR1—muscle cancer	1.58e-06	0.000682	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CNR1—muscle cancer	1.56e-06	0.000673	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTCH1—muscle cancer	1.56e-06	0.000672	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—KIT—muscle cancer	1.54e-06	0.000665	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTCH1—muscle cancer	1.53e-06	0.000662	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IGF2—muscle cancer	1.5e-06	0.000648	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IGF2—muscle cancer	1.5e-06	0.000647	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IGF2—muscle cancer	1.49e-06	0.000643	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ENO2—muscle cancer	1.46e-06	0.000631	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IGF2—muscle cancer	1.46e-06	0.000629	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IGF2—muscle cancer	1.43e-06	0.000619	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—FOXO4—muscle cancer	1.43e-06	0.000619	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—VEGFA—muscle cancer	1.42e-06	0.000614	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IGF2—muscle cancer	1.42e-06	0.000611	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTCH1—muscle cancer	1.41e-06	0.00061	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CNR1—muscle cancer	1.41e-06	0.000607	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTCH1—muscle cancer	1.39e-06	0.0006	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTCH1—muscle cancer	1.39e-06	0.000599	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—FOXO4—muscle cancer	1.38e-06	0.000597	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTCH1—muscle cancer	1.38e-06	0.000597	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—FOXO1—muscle cancer	1.38e-06	0.000596	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—FOXO1—muscle cancer	1.38e-06	0.000595	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTCH1—muscle cancer	1.38e-06	0.000595	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—FOXO4—muscle cancer	1.38e-06	0.000594	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—FOXO1—muscle cancer	1.37e-06	0.000592	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTCH1—muscle cancer	1.37e-06	0.000589	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—KIT—muscle cancer	1.36e-06	0.000588	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTCH1—muscle cancer	1.36e-06	0.000588	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CNR1—muscle cancer	1.36e-06	0.000586	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IGF2—muscle cancer	1.36e-06	0.000585	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CNR1—muscle cancer	1.35e-06	0.000583	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—FOXO1—muscle cancer	1.34e-06	0.000579	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—FOXO4—muscle cancer	1.34e-06	0.000578	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—VEGFA—muscle cancer	1.33e-06	0.000574	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—FOXO1—muscle cancer	1.32e-06	0.00057	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—FH—muscle cancer	1.32e-06	0.00057	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—FOXO4—muscle cancer	1.32e-06	0.000569	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CNR1—muscle cancer	1.31e-06	0.000567	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—FOXO1—muscle cancer	1.3e-06	0.000562	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CNR1—muscle cancer	1.29e-06	0.000558	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IGF2—muscle cancer	1.29e-06	0.000558	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IGF2—muscle cancer	1.27e-06	0.00055	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTCH1—muscle cancer	1.26e-06	0.000546	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—FOXO1—muscle cancer	1.25e-06	0.000538	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—FOXO4—muscle cancer	1.22e-06	0.000525	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—MDM2—muscle cancer	1.21e-06	0.000524	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—FOXO4—muscle cancer	1.2e-06	0.000516	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—FOXO4—muscle cancer	1.19e-06	0.000515	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CNR1—muscle cancer	1.19e-06	0.000515	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—FOXO4—muscle cancer	1.19e-06	0.000513	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—FOXO1—muscle cancer	1.19e-06	0.000513	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—FOXO4—muscle cancer	1.19e-06	0.000512	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—FOXO4—muscle cancer	1.17e-06	0.000507	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CNR1—muscle cancer	1.17e-06	0.000507	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—FOXO1—muscle cancer	1.17e-06	0.000506	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CNR1—muscle cancer	1.17e-06	0.000505	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—FOXO4—muscle cancer	1.17e-06	0.000505	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CNR1—muscle cancer	1.17e-06	0.000504	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CNR1—muscle cancer	1.16e-06	0.000502	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CNR1—muscle cancer	1.15e-06	0.000497	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IGF2—muscle cancer	1.15e-06	0.000497	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CNR1—muscle cancer	1.15e-06	0.000496	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—MED12—muscle cancer	1.14e-06	0.000492	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IGF2—muscle cancer	1.11e-06	0.000479	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IGF2—muscle cancer	1.1e-06	0.000477	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—FOXO4—muscle cancer	1.09e-06	0.00047	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—VEGFA—muscle cancer	1.08e-06	0.000466	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—TP53—muscle cancer	1.08e-06	0.000464	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IGF2—muscle cancer	1.07e-06	0.000464	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MDM2—muscle cancer	1.07e-06	0.000463	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CNR1—muscle cancer	1.07e-06	0.000461	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—FOXO1—muscle cancer	1.06e-06	0.000457	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IGF2—muscle cancer	1.06e-06	0.000457	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KIT—muscle cancer	1.05e-06	0.000454	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KIT—muscle cancer	1.05e-06	0.000454	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KIT—muscle cancer	1.04e-06	0.000451	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ENO2—muscle cancer	1.04e-06	0.000449	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KIT—muscle cancer	1.02e-06	0.000441	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—FOXO1—muscle cancer	1.02e-06	0.000441	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—FOXO1—muscle cancer	1.02e-06	0.000439	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KIT—muscle cancer	1.01e-06	0.000434	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—TP53—muscle cancer	1e-06	0.000434	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KIT—muscle cancer	9.93e-07	0.000428	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—FOXO1—muscle cancer	9.89e-07	0.000427	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IGF2—muscle cancer	9.75e-07	0.000421	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—FOXO1—muscle cancer	9.73e-07	0.00042	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MED12—muscle cancer	9.66e-07	0.000417	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IGF2—muscle cancer	9.6e-07	0.000414	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IGF2—muscle cancer	9.57e-07	0.000413	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IGF2—muscle cancer	9.54e-07	0.000412	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IGF2—muscle cancer	9.51e-07	0.000411	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KIT—muscle cancer	9.5e-07	0.00041	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IGF2—muscle cancer	9.42e-07	0.000407	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IGF2—muscle cancer	9.4e-07	0.000406	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—VEGFA—muscle cancer	9.21e-07	0.000398	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KIT—muscle cancer	9.06e-07	0.000391	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—FOXO1—muscle cancer	8.97e-07	0.000387	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KIT—muscle cancer	8.94e-07	0.000386	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—FOXO1—muscle cancer	8.83e-07	0.000381	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—FOXO1—muscle cancer	8.81e-07	0.00038	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ENO2—muscle cancer	8.81e-07	0.00038	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—FOXO1—muscle cancer	8.78e-07	0.000379	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—FOXO1—muscle cancer	8.76e-07	0.000378	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IGF2—muscle cancer	8.73e-07	0.000377	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—FOXO1—muscle cancer	8.67e-07	0.000374	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—FOXO1—muscle cancer	8.65e-07	0.000373	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MDM2—muscle cancer	8.29e-07	0.000358	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MDM2—muscle cancer	8.28e-07	0.000357	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MDM2—muscle cancer	8.22e-07	0.000355	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—muscle cancer	8.16e-07	0.000352	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—VEGFA—muscle cancer	8.15e-07	0.000352	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KIT—muscle cancer	8.07e-07	0.000348	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MDM2—muscle cancer	8.05e-07	0.000348	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—FOXO1—muscle cancer	8.03e-07	0.000347	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MDM2—muscle cancer	7.92e-07	0.000342	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MDM2—muscle cancer	7.82e-07	0.000337	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KIT—muscle cancer	7.79e-07	0.000336	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KIT—muscle cancer	7.75e-07	0.000334	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KIT—muscle cancer	7.54e-07	0.000325	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MDM2—muscle cancer	7.49e-07	0.000323	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MED12—muscle cancer	7.46e-07	0.000322	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KIT—muscle cancer	7.42e-07	0.00032	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MDM2—muscle cancer	7.13e-07	0.000308	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PTGS2—muscle cancer	7.05e-07	0.000304	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MDM2—muscle cancer	7.04e-07	0.000304	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—muscle cancer	6.96e-07	0.0003	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.89e-07	0.000297	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PTGS2—muscle cancer	6.84e-07	0.000295	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KIT—muscle cancer	6.84e-07	0.000295	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ENO2—muscle cancer	6.8e-07	0.000293	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KIT—muscle cancer	6.73e-07	0.00029	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KIT—muscle cancer	6.71e-07	0.00029	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KIT—muscle cancer	6.69e-07	0.000289	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KIT—muscle cancer	6.67e-07	0.000288	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KIT—muscle cancer	6.61e-07	0.000285	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KIT—muscle cancer	6.59e-07	0.000284	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MDM2—muscle cancer	6.35e-07	0.000274	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—VEGFA—muscle cancer	6.29e-07	0.000272	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—VEGFA—muscle cancer	6.29e-07	0.000271	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—VEGFA—muscle cancer	6.24e-07	0.00027	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—muscle cancer	6.16e-07	0.000266	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MDM2—muscle cancer	6.13e-07	0.000265	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KIT—muscle cancer	6.12e-07	0.000264	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—VEGFA—muscle cancer	6.11e-07	0.000264	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MDM2—muscle cancer	6.1e-07	0.000263	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTGS2—muscle cancer	6.06e-07	0.000261	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—VEGFA—muscle cancer	6.02e-07	0.00026	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—VEGFA—muscle cancer	5.94e-07	0.000256	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MDM2—muscle cancer	5.94e-07	0.000256	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MDM2—muscle cancer	5.84e-07	0.000252	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—VEGFA—muscle cancer	5.68e-07	0.000245	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTGS2—muscle cancer	5.56e-07	0.00024	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—VEGFA—muscle cancer	5.42e-07	0.000234	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MDM2—muscle cancer	5.39e-07	0.000232	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—VEGFA—muscle cancer	5.34e-07	0.000231	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MDM2—muscle cancer	5.3e-07	0.000229	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MDM2—muscle cancer	5.29e-07	0.000228	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MDM2—muscle cancer	5.27e-07	0.000228	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MDM2—muscle cancer	5.25e-07	0.000227	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MDM2—muscle cancer	5.2e-07	0.000225	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MDM2—muscle cancer	5.19e-07	0.000224	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—muscle cancer	5.09e-07	0.00022	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—muscle cancer	4.83e-07	0.000208	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MDM2—muscle cancer	4.82e-07	0.000208	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—muscle cancer	4.75e-07	0.000205	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—muscle cancer	4.75e-07	0.000205	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—muscle cancer	4.72e-07	0.000204	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—muscle cancer	4.66e-07	0.000201	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—muscle cancer	4.63e-07	0.0002	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—muscle cancer	4.62e-07	0.000199	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—muscle cancer	4.55e-07	0.000196	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—muscle cancer	4.51e-07	0.000195	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—muscle cancer	4.49e-07	0.000194	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—muscle cancer	4.44e-07	0.000191	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—muscle cancer	4.3e-07	0.000185	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—muscle cancer	4.09e-07	0.000177	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—muscle cancer	4.09e-07	0.000177	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—muscle cancer	4.04e-07	0.000174	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—muscle cancer	4.02e-07	0.000174	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—muscle cancer	4.02e-07	0.000173	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—muscle cancer	4e-07	0.000173	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—muscle cancer	3.99e-07	0.000172	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—muscle cancer	3.95e-07	0.000171	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—muscle cancer	3.94e-07	0.00017	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—muscle cancer	3.66e-07	0.000158	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—muscle cancer	3.65e-07	0.000157	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—muscle cancer	3.62e-07	0.000156	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—muscle cancer	3.52e-07	0.000152	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—muscle cancer	3.5e-07	0.000151	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—muscle cancer	3.41e-07	0.000147	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—muscle cancer	3.35e-07	0.000145	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—muscle cancer	3.09e-07	0.000133	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—muscle cancer	3.07e-07	0.000132	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—muscle cancer	3.04e-07	0.000131	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—muscle cancer	3.03e-07	0.000131	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—muscle cancer	3.02e-07	0.000131	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—muscle cancer	3.01e-07	0.00013	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—muscle cancer	2.99e-07	0.000129	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—muscle cancer	2.98e-07	0.000129	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—muscle cancer	2.77e-07	0.000119	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—muscle cancer	2.37e-07	0.000102	CbGpPWpGaD
